S. Pini, N. Baldini Rossi, D. Bravi, P. Donda - Vol. 6, Marzo 2000, num.1
Testo Immagini Bibliografia Summary Riassunto Indice
La fluoxetina nel trattamento del disturbo
distimico
Fluoxetine in the treatment of dysthymic disorder
Dysthymic Disorder, according to DSM-IV criteria, comprises different depressive syndromes characterized by having an early onset and a protracted course. Dysthymic Disorder is distressing and disabling, and, compared to major depressive episode, remits in a smaller proportion of cases. Data from the literature indicate that tricyclic antidepressants (TCAs) are effective for dysthymia. However, anticholinergic side-effects have limited the acceptance of this class of drugs. Several controlled studies showed that selective serotonin reuptake inhibitors (SSRIs), in particular, fluoxetine and sertraline, may be effective for dysthymia as much as are TCAs. In addition, the fact that SSRIs are usually associated with high patient’s rate of compliance with treatment promoted this class of drugs as first-choice pharmacological treatment for dysthymia. Among SSRIs, fluoxetine, has been most extensively studied and resulted to be effective and safe in reducing symptomatology in patients with dysthymic disorder.